Key points from article :
Antoxerene focused on small molecule drug discovery for pathways of aging, announced a joint venture with Juvenescence Limited.
The joint venture, FoxBio, will develop Antoxerene’s collection of small molecules that target senescent cells.
Juvenescence will support the venture with $10 million in equity financing and drug development expertise.
“As molecular pathways unique to senescent cells have begun to be identified, we can now develop drugs to target these pathways,” - Kelsey Moody, CEO at Antoxerene.
“This is one of the main focus - modify aging through the clearance of senescent cells” - Greg Bailey, CEO of Juvenescence.
"The synergies between this platform and our technologies are clear, as we tackle fundamental processes involved in aging," - Declan Doogan, CSO of Juvenescence.
